Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CAR-T design: Elements and their synergistic function
Jayapriya Jayaraman, Michael Mellody, Andrew J. Hou, et al.
EBioMedicine (2020) Vol. 58, pp. 102931-102931
Open Access | Times Cited: 230

Showing 51-75 of 230 citing articles:

Mechanisms of CAR T cell exhaustion and current counteraction strategies
Xiaoying Zhu, Qing Li, Xiaojian Zhu
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 26
Anti-BCMA novel therapies for multiple myeloma
Vincenzo Sammartano, Marta Franceschini, Sara Fredducci, et al.
Cancer Drug Resistance (2023) Vol. 6, Iss. 1, pp. 169-181
Open Access | Times Cited: 17
CAR-T State of the Art and Future Challenges, A Regulatory Perspective
Lorenzo Giorgioni, Alessandra Ambrosone, Maria Francesca Cometa, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11803-11803
Open Access | Times Cited: 17
Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape
You Zhai, Yicong Du, LI Guan-zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 16
CAR-T cell therapy for hematological malignancies: History, status and promise
Chao Wang, Jianpeng Wang, Shusheng Che, et al.
Heliyon (2023) Vol. 9, Iss. 11, pp. e21776-e21776
Open Access | Times Cited: 15
Tuning spacer length improves the functionality of the nanobody-based VEGFR2 CAR T cell
Fatemeh Taheri, Mahmoud Hassani, Zahra Sharifzadeh, et al.
BMC Biotechnology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Selective refueling of CAR T cells using ADA1 and CD26 boosts antitumor immunity
Yue Hu, Abhijit Sarkar, Kevin Song, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 5, pp. 101530-101530
Open Access | Times Cited: 4
CAR-T Cell Therapy in Pancreatic and Biliary Tract Cancers: An Updated Review of Clinical Trials
Konstantinos Drougkas, Konstantinos Karampinos, Ioannis Karavolias, et al.
Journal of Gastrointestinal Cancer (2024) Vol. 55, Iss. 3, pp. 990-1003
Closed Access | Times Cited: 4
Recent advances in CAR‐T cell therapy for acute myeloid leukaemia
C. Gao, Xin Li, Yao Xu, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 9
Open Access | Times Cited: 4
Comparison of seven CD19 CAR designs in engineering NK cells for enhancing anti‐tumour activity
Yao Wang, Jianhuan Li, Zhiqian Wang, et al.
Cell Proliferation (2024)
Open Access | Times Cited: 4
Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges
Bufan Xiao, Jingtao Zhang, Yuge Zhu, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 35
The potential of CAR T cell therapy for prostate cancer
Philipp Wolf, Jamal Alzubi, Christian Gratzke, et al.
Nature Reviews Urology (2021) Vol. 18, Iss. 9, pp. 556-571
Closed Access | Times Cited: 33
CAR‐Ts: new perspectives in cancer therapy
Rafaela Abrantes, Henrique O. Duarte, Catarina Gomes, et al.
FEBS Letters (2022) Vol. 596, Iss. 4, pp. 403-416
Closed Access | Times Cited: 23
The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity
Yuan He, Martijn Vlaming, Tom van Meerten, et al.
Cancers (2022) Vol. 14, Iss. 2, pp. 299-299
Open Access | Times Cited: 23
Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights and Open Questions
Harish Sudarsanam, Raymund Buhmann, Reinhard Henschler
Frontiers in Bioengineering and Biotechnology (2022) Vol. 10
Open Access | Times Cited: 22
ROR1-targeting switchable CAR-T cells for cancer therapy
Haiyong Peng, Thomas Nerreter, Katrin Mestermann, et al.
Oncogene (2022) Vol. 41, Iss. 34, pp. 4104-4114
Open Access | Times Cited: 22
Development of CAR T Cell Therapy in Children—A Comprehensive Overview
Michael Boettcher, Alexander Joechner, Ziduo Li, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 8, pp. 2158-2158
Open Access | Times Cited: 21
Outline of Salivary Gland Pathogenesis of Sjögren’s Syndrome and Current Therapeutic Approaches
Yoshiaki Yura, Masakazu Hamada
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 11179-11179
Open Access | Times Cited: 13
Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR‐T) Cell Therapy Targeting Delta‐Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Di Zhou, Lauren A. Byers, Beate Sable, et al.
The Journal of Clinical Pharmacology (2023) Vol. 64, Iss. 3, pp. 362-370
Closed Access | Times Cited: 13
Exploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies
Yugu Zhang, Diyuan Qin, Arthur Shou, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 19, pp. 6124-6124
Open Access | Times Cited: 11
Recent Updates on Chimeric Antigen Receptor T-Cell Approaches in Cancer Immunotherapy
Maryam Sahlolbei, Amirhossein Yazdi, Mohadeseh Rostamipoor, et al.
IntechOpen eBooks (2024)
Open Access | Times Cited: 4
Recent advances in immunotherapy in cancer treatment
Ayyub Patel
Cellular and Molecular Biology (2024) Vol. 70, Iss. 5, pp. 89-99
Open Access | Times Cited: 4
Developing CAR-immune cell therapy against SARS-CoV-2: Current status, challenges and prospects
Yizhao Chen, Chong Liu, Yilong Fang, et al.
Biochemical Pharmacology (2024) Vol. 222, pp. 116066-116066
Closed Access | Times Cited: 3
The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma
Irene Straßl, Klaus Podar
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 4, pp. 377-391
Closed Access | Times Cited: 3
Phage Display as a Medium for Target Therapy Based Drug Discovery, Review and Update
Samaneh Jahandar-Lashaki, Safar Farajnia, Aref Faraji-Barhagh, et al.
Molecular Biotechnology (2024)
Closed Access | Times Cited: 3

Scroll to top